LEVI Earnings: Levi Strauss Stock Jumps 5% as Company Raises Guidance
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
San Francisco-based Levi Strauss reported earnings per share (EPS) of $0.22, which topped the consensus forecast among analysts that called for $0.13. Revenue in the year's second quarter totaled $1.45 billion, which was ahead of the $1.37 billion expected on Wall Street. Sales were up 6% from a year earlier.
Looking ahead, Levi Strauss raised its full-year guidance, saying it's working to absorb some of the costs from higher tariffs. The denim maker said it now expects full-year earnings of $1.25 to $1.30 per share, up from a previous forecast of $1.20 and $1.25, and better than the $1.23 that analysts anticipated.
The company expects sales to rise between 1% and 2% this year, up from previous guidance of down 1% to 2%. That range is also ahead of Wall Street expectations, which expected revenue to decline 5.2%.
Levi Strauss' earnings per share. Source: Main Street Data
Assumptions
Levi Strauss' current forecast assumes a 30% tariff on China, where the company manufactures about 1% of its clothing items, and a 10% tariff on the rest of the world. Those assumptions could change as U.S. President Donald Trump negotiates trade deals with key manufacturing regions, notably in Asia.
Management at the company has said that 60% of the products they sell are manufactured outside the U.S. However, for the time being, Levi Strauss said that it plans to absorb the tariff impacts without raising prices on consumers. To that end, the company forecasts that tariffs will impact its business by $25 million to $30 million for the rest of this year, or about two to three cents per share.
LEVI stock has risen 16% this year.
Is LEVI Stock a Buy?
The stock of Levi Strauss has a consensus Strong Buy rating among nine Wall Street analysts. That rating is based on eight Buy and one Hold recommendations issued in the last three months. The average LEVI price target of $20.06 implies 1.67% upside from current levels. These ratings are likely to change after the company's latest financial results.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Hedge fund tycoon Hosking says rival Telegraph bid "ready to go"
The hedge fund founder enlisted to back a bid for The Daily Telegraph says the offer is "ready to go" if a takeover of the broadsheet title involving sovereign Gulf money runs into further regulatory problems. Sky News has learnt that Jeremy Hosking, the prominent City figure who co-founded Marathon Asset Management, is pledging to inject £100m of his own money into the newspaper group if the self-styled 'British bid' of which he is part is successful. Mr Hosking, who now runs Hosking Partners, has been working with Dovid Efune, the owner of the New York Sun, in an effort to gain control of the Telegraph for several months. Money latest: They have been thwarted, though, by an agreement reached with RedBird Capital Partners, the US-based investment firm, to buy the titles for £500m following a two-year battle which has plunged the Telegraph into a protracted state of limbo. RedBird's bid includes tens of millions of pounds of funding from IMI, a state-backed Abu Dhabi vehicle, which cleared a key hurdle last week when the House of Lords voted against a 'fatal motion' which would have blocked the sovereign investment. The outcome of the vote was not without fierce debate, with 155 peers supporting the ban. IMI is controlled by Sheikh Mansour bin Zayed Al Nahyan, the vice-president of the United Arab Emirates and ultimate owner of Manchester City Football Club. Speaking through Mr Efune, Mr Hosking said in a statement on Wednesday morning: "We have been following the latest developments closely and with the best outcome for all Telegraph stakeholders front of mind. "We understand from the Lords debate last week that there is now a legal requirement for the government to formally investigate all the foreign government ties that may result in influence over the current preferred buyer. "Should the buyer be deemed unsuitable, our "British Bid" is ready to go. "We believe our current capitalization is more than adequate to replace the controlling shareholder's portion of the deal. "My own personal commitment is £100m in equity capital." Further details of the financing lined up by Mr Efune's consortium remain unclear, including the level of debt attached to his prospective offer. The RedBird-led acquisition of the Telegraph remains subject to investigations by both Ofcom and the Competition and Markets Authority, which are likely to delay completion of the deal into next year. Sky News previously revealed that Sir Leonard Blavatnik, owner of the DAZN sports streaming platform, and Daily Mail proprietor Lord Rothermere were preparing to buy minority stakes as part of the RedBird transaction. Gerry Cardinale, the RedBird executive, who has spearheaded the latest iteration of its acquisition, has described the firm as "the right owner at the right time". RedBird said in May that it was "in discussions with select UK-based minority investors with print media expertise and strong commitment to upholding the editorial values of the Telegraph". The Telegraph titles' parent company was forced into insolvency proceedings in 2023 by Lloyds Banking Group, which ran out of patience with the Barclay family, their long-standing owner. RedBird IMI, a joint venture between the two firms, paid £600m several months later to acquire a call option that was intended to convert into ownership of the Telegraph newspapers and The Spectator magazine. That objective was thwarted by a change in media ownership laws - which banned any form of foreign state ownership. Some peers argued last week that a 15% threshold was too high and that the legislation to permit it was dangerously ambiguous because it could allow for more than one state investor to aggregate their holdings in British newspapers. A further statutory instrument will need to be approved in order to address this issue. The Spectator, which had also been part of the same group, was sold last year for £100m to Sir Paul Marshall, the hedge fund billionaire, who has installed Lord Gove, the former cabinet minister, as its editor.
Entrepreneur
7 minutes ago
- Entrepreneur
W Health Ventures Launches USD70M Fund II to Build New-Age Healthcare Startups in India
The fund aims to back 8 to 10 new ventures over the next four years You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Early-stage investor W Health Ventures has launched its second fund worth USD 70 million, doubling down on its unique company-creation model to build healthcare startups from scratch in India. The fund aims to back 8 to 10 new ventures over the next four years, with a focus on single-specialty care platforms and AI-enabled healthcare services. The launch comes at a time when India's USD370 billion healthcare sector is undergoing transformation, with rising demand for quality, patient-centric care and increasing global interest in Indian healthcare products and services. Despite the growth, healthcare remains a difficult sector to crack for startups, given the regulatory, clinical, and relationship-driven complexities. W Health Ventures hopes to bridge this gap through an active incubation model in partnership with 2070 Health, India's first healthcare venture studio. The firm plans to embed startup infrastructure, a platform team, and strategic capital from the ground up. "Healthcare innovation in India remains 10-15 years behind global benchmarks. This gap is a generational opportunity," said Dr. Pankaj Jethwani, Managing Partner at W Health Ventures. "That is why, over the past five years, we have built the infrastructure to identify white spaces, partner with exceptional founders, and accelerate their journey through proven playbooks, anchor customers, and a seasoned platform team." W Health's first fund backed 12 companies that collectively serve more than 25 million patients worldwide. Its portfolio includes startups like BeatO (diabetes), Mylo (parenting), BabyMD (paediatrics), and AI-driven platforms such as Wysa and Reveal HealthTech. With Fund II, the firm is sharpening its focus on two tested themes: specialty care platforms that address critical clinical gaps in India, and B2B healthcare services leveraging AI and Indian clinical-engineering talent to serve US-based firms. The firm has already started deploying capital from the new fund. One of its first investments, EverHope Oncology, was founded to rethink cancer care in India by offering advanced diagnostics, therapies, and outpatient treatment spaces closer to patients' homes. The startup received a USD10 million day-zero investment led by Narayana Health.
CNBC
8 minutes ago
- CNBC
UBS CEO: Trump tariffs will impact consumption and inflation
UBS CEO Sergio Ermotti discusses the bank's better-than-expected quarterly results and the impact of U.S. President Donald Trump's tariffs on European exporters.
